Harrow Health (HROW)
NASDAQ:HROW
Want to see HROW full AI Analyst Report?
HROW Stock Chart & Stats
$41.50
-$0.36(-1.00%)
At close: 4:00 PM EST
$41.50
-$0.36(-1.00%)
Day’s Range― - ―
52-Week Range$26.87 - $54.85
Previous CloseN/A
Volume51.77K
Average Volume (3M)882.63K
Market Cap
$1.31B
Enterprise Value$1.52B
Total Cash (Recent Filing)$94.64M
Total Debt (Recent Filing)$300.67M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding37,275,110
10 Day Avg. Volume870,857
30 Day Avg. Volume882,626
Financial Highlights & Ratios
PEG Ratio4.91
Price to Book (P/B)34.35
Price to Sales (P/S)6.61
P/FCF Ratio41.91
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue5.65
Enterprise Value/Gross Profit7.63
Enterprise Value/Ebitda38.03
Forecast
1Y Price Target
$67.17Price Target Upside61.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.3
Revenue Forecast (FY)$348.47M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Improving Cash FlowSustained ~74–75% gross margins indicate durable product-level economics across Harrow’s ophthalmic portfolio, while a return to positive operating and free cash flow in 2025/TTM supports reinvestment in commercialization and product launches. This improves long-term funding flexibility versus earlier years, even though cash flow remains somewhat volatile.
VEVYE Market Share And Prescription MomentumVEVYE’s rapid prescriber adoption, sequential NRx/TRx growth and surpassing an incumbent on monthly prescriptions reflect durable clinician and patient demand. Market share gains and a path to >$100M in 2026 suggest a sustainably growing branded revenue stream that underpins recurring sales and strengthens Harrow’s commercial credibility.
Commercial Scale And Multi-product Catalyst PipelineA sizable salesforce expansion plus staged product catalysts (BYOOVIZ/BYQLOVI launches, permanent IOPIDINE J‑code, TRIESENCE and IHEEZO commercialization, G‑MELT development) create multiple durable drivers for revenue diversification. Scaling field resources increases conversion potential and supports mid‑term revenue runway.
Bears Say
Very High LeverageA debt-to-equity ratio near ~10.5 reflects a highly leveraged capital structure that materially raises refinancing, covenant and interest‑coverage risk. Heavy fixed obligations constrain strategic flexibility, increase sensitivity to cash flow swings from product launches, and heighten dilution or refinancing needs if operating improvements stall.
Persistent Net Losses And Negative Adjusted EBITDADespite operational improvements, Harrow remains loss-making with negative adjusted EBITDA in Q1 and recurring net losses historically. Continued unprofitability limits retained earnings and internal funding capacity, increasing reliance on external capital during scale-up and exposing the company to adverse financing terms if market access tightens.
Revenue Volatility And Gross‑to‑net RisksLarge, discrete gross-to-net adjustments and channel inventory timing (IHEEZO ASC absorption) produce uneven reported revenue and obscure demand trends. This structural volatility complicates forecasting, working‑capital planning and net pricing realization, and could erode investor and payor confidence until net pricing protections and reporting lags are fully resolved.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $26.87 and its highest was $54.85 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.31B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Aug 11, 2026 which is in 72 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on May 11, 2026. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.399 by -$0.341.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is -0.17.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,275,110 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.399. Following the earnings report the stock price went down -23.686%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Harrow Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.17 (61.85% Upside)
$67.17 (61.85% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 682.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.44%
12-Months-Change
Fundamentals
Return on Equity
-33.65%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized consistently strong and accelerating demand across Harrow's core commercial products (VEVYE, IHEEZO, TRIESENCE), successful commercial investments (significant salesforce expansion), operational recoveries (Access+), multiple upcoming catalysts (multiunit packaging, clinical data, BYOOVIZ/BYQLOVI launches, IOPIDINE J-code) and reaffirmed full-year guidance. The principal near-term negative was a discrete $8M VEVYE gross-to-net revenue reduction driven by an unexpected high-deductible patient mix and reporting lags, plus a negative adjusted EBITDA in Q1 and some channel inventory timing for IHEEZO. Management identified and implemented corrective actions and expects sequential improvement beginning in Q2 and stronger performance in H2 2026. Overall, positives around demand, market share gains, commercial scale and pipeline progress substantially outweigh the discrete operational and timing headwinds.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$67.17
▲(61.85% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
20.11% Insiders
9.78% Mutual Funds
24.26% Other Institutional Investors
34.52% Public Companies and Individual Investors